文献速递脊柱外科

胰高血糖素样肽-1受体激动剂使用与退变性脊柱疾病胸椎和/或腰椎融合术后并发症的关联:一项按体重指数分层的回顾性研究

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease: A BMI-Stratified Retrospective Study.
PubMed 文献 · Spine (Phila Pa 1976) · 2025-09-04

这项回顾性队列研究利用2010—2023年全国理赔数据库,将术前6个月内使用GLP-1受体激动剂(RA)的胸椎和/或腰椎融合术患者按年龄、性别和Charlson合并症指数(CCI)以4:1匹配对照,并按6个BMI分层分析90天内科并发症及2年和10年手术并发症。结果显示,在BMI≥25的各层中,GLP-1 RA使用者的90天内科并发症显著减少;在BMI 35.0至39.9和≥40.0组中,2年手术并发症较低;10年时,部分BMI组的翻修风险显著降低。结论认为,GLP-1 RA使用与围手术期及长期手术并发症减少相关,尤其在BMI≥25的患者中。

要点

  • 在BMI≥25的各层中,GLP-1 RA使用者的90天内科并发症(感染、肺炎、血栓栓塞、脓毒症、卒中、尿路感染)显著减少。
  • 在BMI 35.0至39.9组,2年假关节相关翻修率为1.1% vs 1.6%(P=0.007),机械失败翻修率为0.8% vs 1.2%(P=0.038)。
  • 10年时,BMI 25.0至29.9组翻修风险HR 0.79(P=0.046);假关节翻修在BMI 35.0至39.9组HR 0.69(P=0.014)、≥40.0组HR 0.73(P=0.041);机械失败翻修在BMI 35.0至39.9组HR 0.65(P=0.013)、≥40.0组HR 0.57(P=0.003)。

核心结论

  • GLP-1 RA使用与退变性脊柱疾病胸椎和/或腰椎融合术患者围手术期及长期手术并发症减少相关,尤其在BMI≥25的患者中。
  • 这种风险降低可能归因于体重减轻和/或这些药物的全身代谢、炎症和血管益处。

研究设计与样本

  • 回顾性队列研究,使用2010—2023年全国理赔数据库,纳入因退变性脊柱疾病行胸椎和/或腰椎融合术的患者。
  • 术前6个月内使用GLP-1 RA者按年龄、性别和CCI以4:1匹配对照,匹配在6个BMI分层内进行。
  • 共纳入291,677例患者,其中19,232例GLP-1 RA使用者与76,778例对照匹配。
  • 结局包括90天内科并发症及2年和10年手术并发症(如感染、假关节和机械失败相关翻修)。
  • 统计分析采用χ²检验、t检验和Cox模型。

主要发现

  • 在BMI≥25的各层中,GLP-1 RA使用者的90天内科并发症(感染、肺炎、血栓栓塞、脓毒症、卒中、尿路感染)显著减少。
  • 2年手术并发症在BMI 35.0至39.9组中,GLP-1 RA使用者较低:假关节相关翻修1.1% vs 1.6%(P=0.007),机械失败翻修0.8% vs 1.2%(P=0.038);在BMI≥40.0组中也较低。
  • 10年时,GLP-1 RA使用与BMI 25.0至29.9组翻修风险显著降低相关(HR 0.79,P=0.046)。
  • 10年时,假关节相关翻修在BMI 35.0至39.9组(HR 0.69,P=0.014)和≥40.0组(HR 0.73,P=0.041)降低。
  • 10年时,机械失败相关翻修在BMI 35.0至39.9组(HR 0.65,P=0.013)和≥40.0组(HR 0.57,P=0.003)降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Retrospective cohort. SUMMARY OF BACKGROUND DATA: Spinal fusions are common interventions for degenerative spine disease (DSD), with increasing utilization in obese and metabolic syndrome populations. Glucagon-like peptide-1 (GLP-1) receptor agonists (RA), widely adopted for diabetes and weight management, may offer systemic benefits that exert a parallel influence on surgical outcomes. OBJECTIVE: We aimed to evaluate whether preoperative GLP-1 RA use influences 90-day medical and 2- and 10-year surgical complications following thoracic and/or lumbar spinal fusion for DSD, stratified by BMI. METHODS: Using a national claims database (2010-2023), we identified patients undergoing thoracic and/or lumbar spinal fusion for degenerative conditions. GLP-1 RA users within 6 months pre-op were 4:1 matched to controls by age, sex, and CCI across six BMI strata. Outcomes included 90-day medical and 2- and 10-year surgical complications (eg, revisions for infection, pseudoarthrosis, and mechanical failure). χ 2 , t tests, and Cox models were used for statistical analysis. RESULTS: Among 291,677 patients, 19,232 GLP-1 RA users were matched to 76,778 controls. Ninety-day medical complications-such as infection, pneumonia, thromboembolism, sepsis, stroke, and UTI-were significantly reduced in GLP-1 RA users across BMI categories ≥25. Two-year surgical complications were lower among GLP-1 RA users in BMI 35 ti 39.9 (1.1% vs . 1.6%, P =0.007 for pseudarthrosis-related revision; 0.8% vs . 1.2%, P =0.038 for mechanical failure) and ≥40 groups. At 10 years, GLP-1 RA use was associated with significantly reduced risk of revision in the 25.0 to 29.9 (HR 0.79, P =0.046) BMI group. Revision due to pseudarthrosis was reduced in BMI 35.0 to 39.9 (HR 0.69, P =0.014) and ≥40.0 (HR 0.73, P =0.041), while revision for mechanical failure was lower in BMI 35.0 to 39.9 (HR 0.65, P =0.013) and ≥40.0 (HR 0.57, P =0.003). CONCLUSION: GLP-1 RA use was linked with reduced perioperative and long-term surgical complications in patients undergoing thoracic and/or lumbar fusions for degenerative spine disease, particularly in those with BMI ≥25. This risk reduction may be attributed to weight loss and/or the systemic metabolic, inflammatory, and vascular benefits of these medications.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Kishan A, Khela HS, Carayannopoulos NL, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease: A BMI-Stratified Retrospective Study. Spine (Phila Pa 1976). 2025. PMID: 40905270. doi:10.1097/BRS.0000000000005494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。